Literature DB >> 26155169

Vitamin D deficiency is related to thyroid antibodies in autoimmune thyroiditis.

Asli Dogruk Unal1, Ozlem Tarcin1, Hulya Parildar2, Ozlem Cigerli2, Hacer Eroglu3, Nilgun Guvener Demirag1.   

Abstract

INTRODUCTION: It has been known that vitamin D has some immunomodulatory effects and in autoimmune thyroid diseases, vitamin D deficiency was more prevalent. In this study, our aim was to investigate the relationship between thyroid autoantibodies and vitamin D.
MATERIAL AND METHODS: Group 1 and 2 consisted of 254 and 27 newly diagnosed Hashimoto's thyroiditis (HT) and Graves' disease (GD) cases, respectively; age-matched 124 healthy subjects were enrolled as controls (group 3). All subjects (n = 405) were evaluated for 25OHD and thyroid autoantibody [anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-tg)] levels.
RESULTS: Group 2 and group 1 patients had lower 25OHD levels than group 3 subjects 14.9 ±8.6 ng/ml, 19.4 ±10.1 ng/ml and 22.5 ±15.4 ng/ml, respectively (p < 0.001). Serum 25OHD levels inversely correlated with anti-tg (r = -0.136, p = 0.025), anti-TPO (r = -0.176, p = 0.003) and parathormone (PTH) (r = -0.240, p < 0.001). Group 2 patients had higher anti-tg and anti-TPO levels than group 1 and 3 (p < 0.001).
CONCLUSIONS: In this study, we found that patients with autoimmune thyroid disease (AITD) present with lower vitamin D levels and GD patients have higher prevalence. Since we found an inverse correlation between vitamin D levels and thyroid antibody levels, we may suggest that vitamin D deficiency is one of the potential factors in pathogenesis of autoimmune thyroid disorders.

Entities:  

Keywords:  autoimmunity; thyroid; vitamin D

Year:  2014        PMID: 26155169      PMCID: PMC4439962          DOI: 10.5114/ceji.2014.47735

Source DB:  PubMed          Journal:  Cent Eur J Immunol        ISSN: 1426-3912            Impact factor:   2.085


Introduction

Vitamin D is a lipid soluble vitamin which affects via vitamin D receptor (VDR). Vitamin D receptor is an intracellular receptor which belongs to the steroid/thyroid nuclear receptor family. This receptor is located in many immune cells, such as neutrophils, macrophages, dendritic cells, T and B cells. In recent years, apart from its primary role in bone and mineral homeostasis, it has been shown that vitamin D has potent immunomodulatory effects both on the innate and adaptive immune system [1-4]. Vitamin D inhibits pro-inflammatory processes by suppressing the over-activity of CD4+, Th1, Th2 and Th17 cells and the production of their related cytokines by the activation of VDR [1, 5]. Epidemiological studies have shown a relation between vitamin D deficiency and autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus and autoimmune thyroiditis [6-8]. Autoimmune thyroid diseases (AITDs), including Graves’ disease (GD), Hashimoto's thyroiditis (HT) and postpartum thyroiditis, are the most frequently seen autoimmune diseases affecting more than 5% of population. In recent years, there have been a few studies demonstrating an increase in vitamin D deficiency in HT [9, 10]. In this study, our aim was to compare vitamin D levels of newly diagnosed AITDs (GD and HT) and healthy controls and investigate the relation between thyroid autoantibodies and vitamin D deficiency.

Material and methods

This study was approved by the Baskent University Institutional Review Board and Ethics Committee (Project no. KA13/176) and supported by the Baskent University Research Fund. Informed consent was obtained from all patients and healthy controls.

Study population

This study population consisted of newly diagnosed AITD adult patients and controls. According to diagnosis, the study population was separated into three different groups. Hashimoto's thyroiditis patients (diagnosed by elevated antithyroid peroxidase and antithyroglobulin antibodies (TPOAb, TgAb) and basal thyrotrophic hormone (TSH) as well as typical hypoechogenicity of the thyroid in high resolution sonography) were included in group 1, GD patients [diagnosed by elevated free thyroxine (fT4) and suppressed TSH levels and the presence of diffused goiter and thyroid receptor antibody (TRAb) positivity] in group 2 and controls in group 3. Patients with primary liver and renal failure, diabetes mellitus, metabolic bone disorders, hyperparathyroidism, malignancy, previously known thyroid disorders and on oral contraceptive, anticonvulsant, anti-osteoporotic therapy and other medications that might alter 25(OH)D or 1,25(OH)2D metabolism and thyroid functions had been excluded from the study.

Laboratory investigation

For measuring 25(OH)D, TSH, anti-TPO and anti-tg, a blood sample was collected by venipuncture at the fasting state, the serum was separated by centrifugation and then stored at –70°C for a week until analysed. Vitamin D: Vitamin D status was evaluated by measurement of serum 25(OH)D levels with a chemiluminescent immunoassay method (Architect i1000 system); normal range was 8.8-46.3 ng/ml (winter); and the intra-assay CV ranged from 2.6 to 4.0%. Serum 25(OH)D levels below 20 ng/ml were considered as deficiency. Parathormone: Serum PTH levels were measured with an electrochemiluminescent immunoassay method (Architect i2000 system); normal range 15-68 pg/ml; intra- assay CV 3.0-6.5%. Serum calcium (Ca) levels were measured with an enzymatic colorimetric assay (C8000 system); intra-assay and inter-assay CV were 0.5-0.6% and 0.3-0.5%, respectively. Thyrotrophic hormone, anti-tg, and anti-TPO: TSH, anti-tg, and anti-TPO were also measured with a chemiluminescent immunoassay method (CMIA) (Architect i2000 system, Abbott, USA). The assays have intra- assay precision of 4.3%, 5.8%, and 3.2%, respectively. Positive anti-TPO, and anti-tg were defined as a value greater than 5.61 IU/ml and 4.11 IU/ml, respectively.

Statistical analyses

Statistical analyses were performed with the Statistical Package for Social Sciences (SPSS for Windows) software (version 17.0, SPSS Inc., Chicago, IL, USA). All parametric variables were given as mean ± SD or median and interquartile range according to distribution of variables. Distribution of patients was assessed by using visual (histograms, probability plots) and analytical methods (Kolmogorov- Smirnov/Shapiro-Wilk's test). The difference between categorical variables was analyzed with Chisquare test and continuous variables were analyzed with Mann-Whitney U test. As the vitamin D level was not normally distributed even after logarithmic transformation, the data were compared by the non-parametric Mann-Whitney U test. A p-value below 0.05 was considered to be statistically significant. While investigating the associations between non-normally distributed and ordinal variables, the correlation coefficients and their significance were calculated using the Spearman test.

Results

A total of 405 patients were enrolled in our study. The mean age was 44.6 ±13.5 years and 89.4% were women in the study population. There was no age difference between 3 groups (p > 0.05). A mean vitamin D level of all participants was 20.1 ±12 ng/ml. Patients whose serum 25(OH)D levels were below 20 ng/ml were considered as vitamin D deficient. Sixty five percent (183/281) of the AITDs patients were vitamin D deficient. When vitamin D deficient (n = 183) and sufficient (n = 98) AITDs patients were compared, anti-tg and anti-TPO levels found significantly high in the vitamin D deficient group (p = 0.02 and p = 0.003, respectively, for anti-tg and anti-TPO) (Table 1).
Table 1

Thyroid autoantibody levels according to the vitamin D status

Vitamin D deficient group (n = 183)Vitamin D sufficient group (n = 98) p value
Vitamin D (ng/ml)13.4 ±3.629.5 ±100.001
Anti-TG (IU/ml)40.4 1.15-100019.9 1.12-10000.02
Anti-TPO (IU/ml)170.9 0-100036.8 0.06-10000.003

Values are expressed as mean ÷ SD or median with interquartile range

Anti-TG – thyroglobulin antibody, anti-TPO – anti-thyroid peroxidase antibody

Thyroid autoantibody levels according to the vitamin D status Values are expressed as mean ÷ SD or median with interquartile range Anti-TG – thyroglobulin antibody, anti-TPO – anti-thyroid peroxidase antibody Group 1, group 2 and group 3 consisted of 254, 27 and 124 patients, respectively. The prevalence of vitamin D insufficiency was 63% and 85.2% in group 1 and 2, respectively. Although the levels of vitamin D were lowest in group 2 (Fig. 1), calcium and PTH levels were similar between groups. Laboratory results of study population are demonstrated in Table 2.
Fig. 1

Vitamin D levels in each group

Table 2

Characteristics of the study population

Group 1Group 2Group 3 p value
TSH (mIU/ml)2.47 0.16-39.60.01 0.001-0.671.75 0.32-7.43 < 0.001
Anti-TG (IU/ml)29.4 1.12-100071.1 1.61-10001.43 0.46-5.71 < 0.001
Anti-TPO (IU/ml)117.68 0-1000281.36 0-10000.26 0-4.78 < 0.001
PTH (pg/ml)46.9 9.14-135.448.4 25.1-111.243.1 19.9-134.90.07
Vitamin D (ng/ml)17.05 5.4-8014.9 4-3919.9 9-122.7 < 0.001
Ca2+ (mg/dl)9.4 18.4-10.49.5 8.4-10.49.5 8.4-10.20.955

Values are expressed as median with interquartile range.

TSH – thyroid-stimulating hormone, anti-tg – thyroglobulin antibody, anti-TPO – anti-thyroid peroxidase antibody, PTH – parathyroid hormone, Ca – calcium

Vitamin D levels in each group Characteristics of the study population Values are expressed as median with interquartile range. TSH – thyroid-stimulating hormone, anti-tg – thyroglobulin antibody, anti-TPO – anti-thyroid peroxidase antibody, PTHparathyroid hormone, Ca – calcium Multivariate analysis using logistic regression revealed that independent determinants of vitamin D levels were age and sex (r = 0.17, p = 0.004; r = –0.15, p = 0.01, respectively). As expected, there was a negative correlation between vitamin D and PTH levels (r = –0.24, p < 0.001). When we have investigated the association of thyroid autoantibodies, we found that there was a significant correlation between these autoantibodies and vitamin D and TSH levels (Table 3). Thyroid autoantibodies tended to be higher with lower vitamin D levels and higher TSH levels. Serum PTH levels, however, were not associated with anti-tg and anti-TPO levels.
Table 3

Correlation between thyroid autoantibodies and vitamin D and TSH levels

Vitamin DTSH
Anti-TG
r –0.130.144
p 0.0250.018

Anti-TPO
r –0.170.21
p 0.0030.001

TSH – thyroid-stimulating hormone, anti-tg – thyroglobulin antibody, anti-TPO – anti-thyroid peroxidase antibody

Correlation between thyroid autoantibodies and vitamin D and TSH levels TSH – thyroid-stimulating hormone, anti-tg – thyroglobulin antibody, anti-TPO – anti-thyroid peroxidase antibody

Discussion

In recent years, it has been shown that vitamin D has potent immunomodulatory effects and plays important roles in the pathogenesis of autoimmune diseases, apart from its primary role in bone and mineral homeostasis. Furthermore, vitamin D supplementation prevented the onset and development of autoimmune diseases. Active vitamin D regulates T cell response by decreasing the proliferation of Th1 and production of cytokines such as interleukin 2 (IL-2), interferon γ (IFN-γ), tumour necrosis factor (TNF) [3, 11, 12], and shifting the polarization of T cells from Th1 toward Th2 that poduce IL-4 and IL-5 [13]. A third group of Th cells known to be influenced by vitamin D are IL-17-secreting T cells (Th17 cells). 1,25(OH)2D depresses IL-17 production via direct transcriptional suppression [14]. In addition, vitamin D promotes dendritic cell apoptosis and inhibits its differentiation and maturation. Expression of major histocompatibility complex (MHC) II on DC is down regulated by vitamin D [15]. Tolerogenic DCs induced by VDR agonists arrest the development of autoimmune diseases [16-19]. Especially in recent years, there were some study demonstrating increase vitamin D deficiency in HT or GD [9, 10, 20], but to our best knowledge, this is the first study that evaluate the association between thyroid autoantibodies and vitamin D levels. In this case-control study, patients with autoimmune thyroid diseases (HT and GD) had lower 25(OH)D levels than healthy subjects and vitamin D levels were the lowest in GD patients. Since we have known from our previous and other Turkish studies that vitamin D deficiency has been a prevalent health problem in our country, we adopted a cutoff level of vitamin D level as 20 ng/ml [21-23]. According to this cutoff value, 60.7% of our study population had vitamin D deficiency. It has been known that vitamin D deficiency is not correlated with severity of hyperthyroidism [24, 25], and antithyroid drugs have immunosuppressive effects. In addition, thyroid hormones relatively affect renal activity of 1α-hydroxlase and plasma 1,25(OH)2D levels [26, 27]. For these reasons, only newly diagnosed AITDs patients were included and we measured 25(OH)D level instead of 1,25(OH)2D in our study. Autoimmune thyroid diseases are relatively common organ-specific autoimmune disorders that cause diseases ranging in severity from hypothyroidism (HT) to hyperthyroidism (GD) [28]. The effects of various environmental factors and the intrinsic genetic predisposition of an individual may lead to a loss of self-tolerance and contribute to the initiation of AITDs. In pathological conditions like thyroiditis, infiltrating lymphocytes, cell surface expression of MHCII, Fas-mediated apoptosis and cytokines released from both immune cells and thyrocytes contribute to amplification and progression of AITD [29-34]. According to this theory, as a result of defective suppressor T cells, Th (CD4) cells are able to activate and cooperate with B lymphocytes. B lymphocytes activated by T lymphocytes produce antibodies that react with thyroid antigens. Studies on HT and GD patients had reported low vitamin D levels [9, 10, 35, 36]. Consistent with the literature, we found a lower vitamin D level in patients with autoimmune thyroiditis (GD group and HT group) than in controls. In addition, this is the first study that found a statistically significant negative correlation between serum 25(OH)D and anti-TPO, anti-tg levels in both HT and GD patients.

Conclusions

Our findings indicate that patients with AITD present with lower vitamin D levels and GD patients have higher prevalence. Since we found an inverse correlation between vitamin D levels and thyroid antibody levels, we might speculate that there might exist a casual relationship. However, these findings do not clarify whether treatment with vitamin D has any beneficial effect on progression or remission of AITD. So, further studies specifically designed to evaluate the beneficial effect of vitamin D supplementation on AITD are needed.
  36 in total

1.  Vitamin D deficiency is a problem for adult out-patients? A university hospital sample in Istanbul, Turkey.

Authors:  Ozlem Cigerli; Hulya Parildar; Aslı D Unal; Ozlem Tarcin; Rengin Erdal; Nilgun Guvener Demirag
Journal:  Public Health Nutr       Date:  2012-08-09       Impact factor: 4.022

2.  Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.

Authors:  H Pantazi; P D Papapetrou
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

Review 3.  Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence.

Authors:  Margherita T Cantorna; Brett D Mahon
Journal:  Exp Biol Med (Maywood)       Date:  2004-12

Review 4.  Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system.

Authors:  Margherita T Cantorna; Yan Zhu; Monica Froicu; Anja Wittke
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

5.  High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors.

Authors:  M Z Erkal; J Wilde; Y Bilgin; A Akinci; E Demir; R H Bödeker; M Mann; R G Bretzel; H Stracke; M F Holick
Journal:  Osteoporos Int       Date:  2006-05-23       Impact factor: 4.507

6.  Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells.

Authors:  Martin Hewison; Lisa Freeman; Susan V Hughes; Katie N Evans; Rosemary Bland; Aristides G Eliopoulos; Mark D Kilby; Paul A H Moss; Ronjon Chakraverty
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

Review 7.  Vitamin D in rheumatoid arthritis.

Authors:  Maurizio Cutolo; Kati Otsa; Maria Uprus; Sabrina Paolino; Bruno Seriolo
Journal:  Autoimmun Rev       Date:  2007-08-14       Impact factor: 9.754

Review 8.  Preventive strategies in systemic lupus erythematosus.

Authors:  Andrea Doria; Silvia Arienti; Mariaelisa Rampudda; Mariagrazia Canova; Michele Tonon; Piercalo Sarzi-Puttini
Journal:  Autoimmun Rev       Date:  2007-12-03       Impact factor: 9.754

9.  Thyroid hormones decrease plasma 1α,25-dihydroxyvitamin D levels through transcriptional repression of the renal 25-hydroxyvitamin D3 1α-hydroxylase gene (CYP27B1).

Authors:  Mina Kozai; Hironori Yamamoto; Mariko Ishiguro; Nagakatsu Harada; Masashi Masuda; Tomohiro Kagawa; Yuichiro Takei; Ayako Otani; Otoki Nakahashi; Shoko Ikeda; Yutaka Taketani; Ken-Ichi Takeyama; Shigeaki Kato; Eiji Takeda
Journal:  Endocrinology       Date:  2013-01-10       Impact factor: 4.736

10.  Two-step development of Hashimoto-like thyroiditis in genetically autoimmune prone non-obese diabetic mice: effects of iodine-induced cell necrosis.

Authors:  M C Many; S Maniratunga; I Varis; M Dardenne; H A Drexhage; J F Denef
Journal:  J Endocrinol       Date:  1995-11       Impact factor: 4.286

View more
  18 in total

Review 1.  Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects.

Authors:  Massimiliano Caprio; Marco Infante; Matilde Calanchini; Caterina Mammi; Andrea Fabbri
Journal:  Eat Weight Disord       Date:  2016-08-23       Impact factor: 4.652

2.  Serum 25-hydoxyvitamin D concentrations in relation to Hashimoto's thyroiditis: a systematic review, meta-analysis and meta-regression of observational studies.

Authors:  Mario Štefanić; Stana Tokić
Journal:  Eur J Nutr       Date:  2019-05-14       Impact factor: 5.614

Review 3.  Association Between Vitamin D Deficiency and Autoimmune Thyroid Disorder: A Systematic Review.

Authors:  Sabah A Khozam; Abdulhadi M Sumaili; Mohammed A Alflan; Rawan As'ad Salameh Shawabkeh
Journal:  Cureus       Date:  2022-06-12

Review 4.  Sunshine vitamin and thyroid.

Authors:  Immacolata Cristina Nettore; Luigi Albano; Paola Ungaro; Annamaria Colao; Paolo Emidio Macchia
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

Review 5.  Vitamin D deficiency as a risk factor for the development of autoantibodies in patients with ASIA and silicone breast implants: a cohort study and review of the literature.

Authors:  Maartje J L Colaris; Rene R van der Hulst; Jan Willem Cohen Tervaert
Journal:  Clin Rheumatol       Date:  2017-03-17       Impact factor: 2.980

6.  Study of Vitamin D Level and Vitamin D Receptor Polymorphism in Hypothyroid Egyptian Patients.

Authors:  Hoda A ElRawi; Nashwa S Ghanem; Naglaa M ElSayed; Hala M Ali; Laila A Rashed; Mai M Mansour
Journal:  J Thyroid Res       Date:  2019-08-26

Review 7.  Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review.

Authors:  D Gallo; L Mortara; M B Gariboldi; S A M Cattaneo; S Rosetti; L Gentile; D M Noonan; P Premoli; C Cusini; M L Tanda; L Bartalena; E Piantanida
Journal:  J Endocrinol Invest       Date:  2019-10-04       Impact factor: 5.467

Review 8.  The Role of Vitamin D in Thyroid Diseases.

Authors:  Dohee Kim
Journal:  Int J Mol Sci       Date:  2017-09-12       Impact factor: 5.923

9.  Effect of Vitamin D deficiency treatment on thyroid function and autoimmunity markers in Hashimoto's thyroiditis: A double-blind randomized placebo-controlled clinical trial.

Authors:  Parichehr Vahabi Anaraki; Ashraf Aminorroaya; Massoud Amini; Fatemeh Momeni; Awat Feizi; Bijan Iraj; Azamosadat Tabatabaei
Journal:  J Res Med Sci       Date:  2017-09-26       Impact factor: 1.852

Review 10.  Thyroid-Gut-Axis: How Does the Microbiota Influence Thyroid Function?

Authors:  Jovana Knezevic; Christina Starchl; Adelina Tmava Berisha; Karin Amrein
Journal:  Nutrients       Date:  2020-06-12       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.